[go: up one dir, main page]

WO2001079274A3 - Tuberculosis antigens and methods of use thereof - Google Patents

Tuberculosis antigens and methods of use thereof Download PDF

Info

Publication number
WO2001079274A3
WO2001079274A3 PCT/DK2001/000276 DK0100276W WO0179274A3 WO 2001079274 A3 WO2001079274 A3 WO 2001079274A3 DK 0100276 W DK0100276 W DK 0100276W WO 0179274 A3 WO0179274 A3 WO 0179274A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tuberculosis antigens
polypeptides
tuberculosis
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2001/000276
Other languages
French (fr)
Other versions
WO2001079274B1 (en
WO2001079274A8 (en
WO2001079274A2 (en
Inventor
Else Marie Agger
Peter Andersen
Li Mei Meng Okkels
Karin Weldingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Priority to AU2001250294A priority Critical patent/AU2001250294A1/en
Priority to EP01923542A priority patent/EP1278769A2/en
Priority to CA002405247A priority patent/CA2405247A1/en
Publication of WO2001079274A2 publication Critical patent/WO2001079274A2/en
Publication of WO2001079274A3 publication Critical patent/WO2001079274A3/en
Publication of WO2001079274B1 publication Critical patent/WO2001079274B1/en
Anticipated expiration legal-status Critical
Publication of WO2001079274A8 publication Critical patent/WO2001079274A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.
PCT/DK2001/000276 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof Ceased WO2001079274A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001250294A AU2001250294A1 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof
EP01923542A EP1278769A2 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof
CA002405247A CA2405247A1 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000666 2000-04-19
DKPA200000666 2000-04-19
DKPA200100283 2001-02-21
DKPA200100283 2001-02-21

Publications (4)

Publication Number Publication Date
WO2001079274A2 WO2001079274A2 (en) 2001-10-25
WO2001079274A3 true WO2001079274A3 (en) 2002-07-11
WO2001079274B1 WO2001079274B1 (en) 2002-08-08
WO2001079274A8 WO2001079274A8 (en) 2004-04-29

Family

ID=26068815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000276 Ceased WO2001079274A2 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1278769A2 (en)
AU (1) AU2001250294A1 (en)
CA (1) CA2405247A1 (en)
WO (1) WO2001079274A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773268B2 (en) 1999-05-04 2004-05-20 Rutgers, The State University Of New Jersey Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
DE10251747A1 (en) * 2002-11-05 2004-05-19 Tuhh-Technologie-Gmbh Genetically modified penicillin amidase and process for its production
WO2004099771A1 (en) * 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
ITRM20040091A1 (en) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie QUICK IMMUNOLOGICAL TEST FOR DIAGNOSIS AND MONITORING OF TUBERCULAR INFECTION.
GB0406271D0 (en) 2004-03-19 2004-04-21 Isis Innovation Diagnostic test
MX2007005256A (en) 2004-11-16 2008-03-11 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors.
KR101035053B1 (en) 2005-06-23 2011-05-19 스태튼스 세룸 인스티튜트 Tuberculosis vaccine containing antigens expressed during the latent period of infection
AU2006272567B2 (en) 2005-07-26 2011-10-06 Rutgers, The State University Of New Jersey Antibody profiles characteristic of tuberculosis state
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
DK2421557T3 (en) 2009-04-24 2019-03-25 Statens Seruminstitut TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP3263124A1 (en) 2009-11-20 2018-01-03 Oregon Health & Science University Methods for producing an immune response to tuberculosis
JP5981436B2 (en) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Use of a Listeria vaccine vector to reverse vaccine unresponsiveness in a parasitically infected subject
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CN108267589B (en) * 2016-12-30 2020-10-23 首都医科大学附属北京胸科医院 Use of Mycobacterium tuberculosis protein in the preparation of products for diagnosing latent tuberculosis infection and/or active pulmonary tuberculosis
GB2621127A (en) * 2022-07-29 2024-02-07 Univ Johannesburg Witwatersrand Vaccine constructs comprising tuberculosis antigens

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044119A1 (en) * 1997-04-02 1998-10-08 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO1998053076A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
WO1998053075A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999024577A1 (en) * 1997-11-10 1999-05-20 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO2000066157A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
WO2000066143A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044119A1 (en) * 1997-04-02 1998-10-08 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO1998053076A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
WO1998053075A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999024577A1 (en) * 1997-11-10 1999-05-20 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO2000066157A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
WO2000066143A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S T COLE ET AL: "Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence", NATURE, vol. 393, 11 June 1998 (1998-06-11), pages 537 - 544, XP002901893 *

Also Published As

Publication number Publication date
EP1278769A2 (en) 2003-01-29
CA2405247A1 (en) 2001-10-25
WO2001079274B1 (en) 2002-08-08
WO2001079274A8 (en) 2004-04-29
WO2001079274A2 (en) 2001-10-25
AU2001250294A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
WO2001079274A8 (en) Tuberculosis antigens and methods of use thereof
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
WO2002094851A3 (en) Peptide vaccines against group a streptococci
IE811595L (en) Synthetic peptide antigens
WO1995029193A3 (en) Melanoma antigens
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
WO1998018930A3 (en) Streptococcus pneumoniae antigens and vaccines
WO2001075087A3 (en) Subtilisin variants
EP1449922A3 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO2002083890A3 (en) Use of clya hemolysin for excretion of fusion proteins
WO2000006736A3 (en) Nucleic acids and proteins from group b streptococcus
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
DE3380629D1 (en) Region-specific determinants for vitamin k dependent bone protein
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
IL138939A0 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
WO1999015692A3 (en) Dengue virus antigens and treatment of dengue fever
AU2002338856A1 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2405247

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001923542

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001250294

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001923542

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 43/2001 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001923542

Country of ref document: EP